PARAMETRIC PORTFOLIO ASSOCIATES LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.

Quarter-by-quarter ownership
PARAMETRIC PORTFOLIO ASSOCIATES LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q1 2022$16,502,000
+14.8%
269,677
-1.8%
0.01%
+28.6%
Q4 2021$14,372,000
+79.2%
274,580
+27.6%
0.01%
+40.0%
Q3 2021$8,022,000
-16.7%
215,195
-8.8%
0.01%0.0%
Q2 2021$9,628,000
+142.8%
235,871
+101.9%
0.01%
+150.0%
Q1 2021$3,965,000
+10.0%
116,854
+3.1%
0.00%0.0%
Q4 2020$3,604,000
-8.8%
113,324
-26.4%
0.00%
-33.3%
Q3 2020$3,952,000
+26.5%
154,031
+26.5%
0.00%
+50.0%
Q2 2020$3,125,000
+99.0%
121,726
+19.1%
0.00%
+100.0%
Q1 2020$1,570,000
-11.4%
102,170
+97.7%
0.00%0.0%
Q4 2019$1,773,000
+464.6%
51,679
+23.0%
0.00%
Q3 2019$314,000
-53.3%
42,012
-18.9%
0.00%
-100.0%
Q2 2019$673,000
+23.9%
51,833
+16.2%
0.00%
Q1 2019$543,000
+196.7%
44,610
+176.9%
0.00%
Q4 2018$183,000
-60.0%
16,109
-23.4%
0.00%
Q3 2018$457,000
+24.9%
21,043
+1.6%
0.00%
Q2 2018$366,000
-67.7%
20,712
-61.5%
0.00%
-100.0%
Q1 2018$1,132,000
+304.3%
53,789
+177.7%
0.00%
Q4 2017$280,000
+18.6%
19,370
+29.5%
0.00%
Q3 2017$236,000
-84.4%
14,954
-83.9%
0.00%
-100.0%
Q1 2017$1,511,000
+457.6%
92,971
+418.1%
0.00%
Q4 2016$271,000
-36.5%
17,944
-36.0%
0.00%
-100.0%
Q3 2016$427,000
-55.3%
28,040
+13.8%
0.00%
-50.0%
Q2 2016$956,000
+252.8%
24,633
+152.3%
0.00%
Q1 2016$271,000
+11.1%
9,763
+114.9%
0.00%
Q4 2015$244,0004,5430.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2018
NameSharesValueWeighting ↓
DCF Advisers, LLC 359,000$18,790,0007.62%
Velan Capital Investment Management LP 150,000$7,851,0006.09%
SILVERARC CAPITAL MANAGEMENT, LLC 195,000$10,206,0004.14%
Vantage Consulting Group Inc 226,670$11,864,0003.19%
Vahanian & Associates Financial Planning Inc. 71,742$3,755,0003.03%
Nicholas Investment Partners, LP 652,886$34,172,0002.16%
COOPER/HAIMS ADVISORS, LLC 61,116$3,199,0001.97%
Bellevue Group AG 3,628,919$189,938,0001.96%
WASATCH ADVISORS LP 8,235,171$431,029,0001.76%
Quantum Private Wealth, LLC 77,622$4,062,0001.54%
View complete list of INTRA CELLULAR THERAPIES INC shareholders